Loss of vesicular dopamine release precedes tauopathy in degenerative dopaminergic neurons in a Drosophila model expressing human tau.

Permalink
https://escholarship.org/uc/item/0571f83x

Journal
Acta neuropathologica, 125(5)

ISSN
0001-6322

Authors
Wu, Ting-Han
Lu, Yu-Ning
Chuang, Chia-Lung
et al.

Publication Date
2013-05-01

DOI
10.1007/s00401-013-1105-x

Peer reviewed
Loss of vesicular dopamine release precedes tauopathy in degenerative dopaminergic neurons in a Drosophila model expressing human tau

Ting-Han Wu · Yu-Ning Lu · Chia-Lung Chuang · Chia-Lin Wu · Ann-Shyn Chiang · David E. Krantz · Hui-Yun Chang

Received: 13 October 2012 / Revised: 7 February 2013 / Accepted: 2 March 2013 / Published online: 15 March 2013 © The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract While a number of genome-wide association studies have identified microtubule-associated protein tau as a strong risk factor for Parkinson’s disease (PD), little is known about the mechanism through which human tau can predispose an individual to this disease. Here, we demonstrate that expression of human wild-type tau is sufficient to disrupt the survival of dopaminergic neurons in a Drosophila model. Tau triggers a synaptic pathology visualized by vesicular monoamine transporter-pHGFP that precedes both the age-dependent formation of tau-containing neurofibrillary tangle-like pathology and the progressive loss of DA neurons, thereby recapitulating the pathological hallmarks of PD. Flies overexpressing tau also exhibit progressive impairments of both motor and learning behaviors. Surprisingly, contrary to common belief that hyperphosphorylated tau could aggravate toxicity, DA neuron degeneration is alleviated by expressing the modified, hyperphosphorylated tauE14. Together, these results show that impairment of VMAT-containing synaptic vesicle, released to synapses before overt tauopathy may be the underlying mechanism of tau-associated PD and suggest that correction or prevention of this deficit may be appropriate targets for early therapeutic intervention.

Keywords Parkinson’s disease · Dopamine · Tau · MAPT · Neuron degeneration · Tauopathy

Introduction

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 1–2 % of people over the age 60, and is characterized by clinical manifestations of bradykinesia, rigidity, resting tremor, and postural instability. These motor defects are thought to result from degeneration of pigmented dopaminergic (DA) neurons in the basal ganglia, particularly those projecting from substantia nigra pars compacta to the striatum [13, 21, 45]. Deposition of Lewy bodies or formation of Lewy neurites, composed of fibrillar aggregates of α-synuclein, are the classical pathological hallmark of PD [48]. However, tau-containing neurofibrillary tangles (NFTs) are also found in the brains of PD patients [60]. Although the inherited forms of PD are rare, genetic variation in PD
susceptibility genes may play a significant role, through gene–environment interactions, in the development of sporadic PD [45].

Microtubule-associated protein tau (MAPT), leucine-rich repeat kinase 2 (LRRK2), and α-synuclein (SNCA) have been identified as the top three PD susceptibility genes [46]. Both SNCA and LRRK2 have been extensively studied in vitro and in vivo; however, the molecular and pathological role of MAPT in PD remains poorly understood [57]. The link between MAPT and disease, originally identified for inherited autosomal dominant frontotemporal dementia and Parkinsonism, is linked to chromosome 17 (FTDP-17). A similar association was later found in several rare atypical Parkinsonism syndromes, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CB) [20, 22, 28]. More recently, a number of studies have suggested that genetic variants in MAPT can also predispose an individual to the development of sporadic and familiar forms of PD [45]. Interestingly, most mutations of MAPT associated with FTDP-17 are located in protein coding sequences for microtubule-binding repeats and splicing sites [22], whereas the mutations identified in allelic variants of MAPT associated with PD are located in upstream regulatory elements [17].

The relationship between human tau and PD is illustrated by a number of genome-wide association studies (GWAS) [16, 32, 38, 46]. The MAPT H1 haplotype is associated with an increased risk of PD [17]. In addition, individuals homozygous for MAPT H1/H1 have an increased susceptibility to develop PD compared to those bearing the heterozygous H1/H2 genotype [59]. Furthermore, some of the MAPT variants appear to increase overall Tau expression [25]. Together, these studies suggest that elevated expression of tau may increase the risk of PD via a genetically gain-of-function mechanism, similar to the duplication of the amyloid precursor proteins gene (APP gene) [43] or duplication or triplication of SNCA (encodes α-synuclein) [47]. However, unlike aberrant copy numbers of APP and SNCA, which have been clearly identified in hereditary AD and PD pedigrees, respectively, evidence for a relationship between MAPT gene dosage and either PD or tauopathies remains primarily circumstantial.

In the present study, we explored whether expression of wild-type MAPT affects DA neurons, the most vulnerable cells in PD, by using a Drosophila animal model. We found that expression of wild-type human tau (htauWT) produces the progressive degeneration of DA neurons. In addition, we observed age-dependent formation of tau-positive, tangle-like pathology in the soma of the DA neurons that was similar to NFTs seen in transgenic mice and AD brains. Flies expressing tau also exhibited motor and learning deficits that coincided with progressive neurodegeneration. Surprisingly, we observed that expression of htauWT caused molecular pathogenesis in synapses, visualized by VMAT-pHluorin localization to nerve terminals that preceded identified pathological events such as tangle formation and overt cell loss. Our results suggest a potential molecular pathological mechanism through which tau may increase the risk of PD.

Materials and methods

Fly strains and genetics

Flies were cultured in standard corn meal–yeast–agar media at 25 °C, and 75 % relative humidity with a light/dark = 12/12 h cycle. Ddc-Gal4 and 996TPH-GAL4 were kindly provided by Jay Hirsh (University of Virginia). UAS-GaMP was obtained from Richard Axel (Department of Biochemistry and Molecular Biophysics, Columbia University). UAS-mCD8-GFP and GMR-GAL4 were obtained from Larry Zipursky (University of California, Los Angeles). Fly strains TH-GAL4, DvlGlut-GAL4, Gad-GAL4, NPF-GAL4, Rhl-GAL4, UAS-actinGFP and tubGAL80ts were used in this study. UAS-htau.1 (II), UAS-htau.2 (III) and UAS-VMA-pHluorin (III) were characterized in this study. UAS-tauAP, UAS-tauE14 and UAS-tauWT were described previously [49, 50].

Molecular cloning and transgenic flies

For generating human tau transgenes, the longest isoform of human tau cDNA, encoding amino acids 1–441, (OriGene Technologies, Rockville, MD), was cloned into pUAST vector using EcoRI and NorI restriction sites. Site-directed mutagenesis was used to generate htau G272V and htau R406W with forward and reverse primer pairs of 5′-GA AGCACCAGCCGGAGTCT-3′ and 5′-CTTCCCCGACTC CTG-3′ for G272V, and 5′-GACACGTCCTCAATGGCAT CTC-3′ and 5′-GAGATGCCATGGAGACGTGTC-3′ for R406W, respectively. The mutations of htau G272V and htau R406W were confirmed by DNA sequencing and subcloned into pUAST expression vector. Germ line transformation and standard fly-balancer crosses were performed. We obtained multiple UAS-htauWT, UAS-htau G272V and UAS-htau R406W transgenic lines. Those with comparable expression level were selected for this study. pHluorin was inserted into the first luminal loop of VMAT and cloned into pUAST vector.

Behavioral analysis

The startle-induced negative geotactic climbing assays were performed as previously described [2, 44]. For locomotion assay, 4-week-old flies (4 weeks after eclosion)
were placed in chambers marked with grids and individual were recorded (videotaped) for periods of 10 min. Locomotion (locomotion index) was manually scored by counting the number of grids individuals crossed per minute. Olfactory associative learning was measured by training 3-week-old adult flies in a T-maze with the Pavlovian conditioning procedure as previously described [52]. Briefly, a group of 100 flies were first exposed to an odor (a conditioned stimulus, CS+) paired with 12 ± 1.5 s pulses of 75 V DC electric shock (an unconditioned stimulus, US). For conditioning order stimulus, we used 3-octanol and 4-methyl-cyclohexanol. This was sequentially followed by presentation of a second odor (CS−) without reinforcement. Performance of conditioned avoidance responses was immediately measured with a choice between CS+ and CS− odors in a T-maze for 2 min after training. A performance index (PI) of aversive learning was calculated as (the number of flies in CS− arm) − (the number of flies in CS+ arm)/(the total number of flies) × 100.

Confocal and electron microscopy

Fly brains and eyes were fixed, stained and mounted in Vectashield (Vector Laboratories, Burlingame, CA) as previously described [9]. Congo-philic stain was performed as previously describe [3]. Confocal microscopic observations of fly brains were performed using a Zeiss LSM 510 laser scanning confocal microscope (Carl-Zeiss, Germany). For characterization of different clusters of DA neurons, Z-stack confocal images that span 50 μm depth were collected from posterior to anterior direction to ensure all posterior clusters are covered. 3D images for each brain are used for examining neuron structure. For presenting purpose, Z-stack images are projected into a single 2D image. For live brain imaging, fly brains were dissected in 1 x PBS and G-CaMP was visualized immediately following brain dissection by confocal microscopy [54]. For VMAT-pHluorin experiments, released sites of VMAT-pHluorin of DA neurons were visualized as previous described [40]. Primary antibodies included mouse tau monclonal antibodies AT8, AT100, and AT180 (Thermo Fisher Scientific, Waltham, MA), rabbit tau polyclonal antibody (Dako, Denmark), and mouse anti-TH (Immunostar, Hudson, WI). Secondary antibodies FITC and Cy3 conjugated anti-mouse or anti-rabbit (Jackson ImmunoResearch Laboratories, West Grove, PA) were used. NIH imageJ64 was used for quantification of G-CaMP and GFP using monochrome images, by measuring pixel intensity, as relative fluorescence with fluorescence-background calibration. For presenting G-CaMP activity, signal intensity was transformed to the pseudocolored thermal scale. Scanning electron microscopy was used to analyze fly eye morphology as previously described [10]. For pair-helical filament examination, transmission electron microscopy (TEM) was used as previously described [23], with the following modifications. Briefly, a resuspended sarkosyl insolubility pellet was placed on a carbon-coated copper grid (75 mesh) and stained with 1 % uranyl acetate. Samples were examined using HT7700 TEM (Hitachi).

Western blots and sarkosyl insolubility assay

To detect the protein expression level, aged fly brains were homogenized in sample buffer using a glass micro-tissue grinder. To enrich tangles, sarkosyl-insoluble fractions of tau were purified from 40 homogenized fly heads as previously described [14] and used for western blot analysis and TEM observation. Standard western blotting procedures were used as previously described [8]. Primary antibodies included mouse cytochrome c (Gene Tex, Irvine, CA), and rabbit cleaved caspase 3 (Cell signaling technology, Danvers, MA). ECL reagents were used for antibody detection (Millipore, Billerica, MA) and imaging was performed using ImageQuant 350 (GE Healthcare).

Results

MAPT overexpression results in the progressive loss of DA neurons

Numerous mutations in MAPT have been linked to FTDP-17, including an increased ratio of the longest 4R Tau isoform [8]. In addition, several GWAS suggest tau variants as a risk factor for PD, and an increased incidence of PD is associated with elevated MAPT levels [16, 25, 32, 36, 38, 46, 55]. These observations suggest that misregulation of tau expression might contribute to the death of dopaminergic neurons. To investigate the effects of human tau overexpression in DA cells, we chose to test the effects of the largest htau WT isoform (2N4R), because an increase of this largest isoform may predispose the susceptibility to PD or some FTDP-17.

Since the most affected neurons in PD are the DA neurons, we used the TH-GAL4 driver to overexpress UAS-htau WT and co-express UAS-mCD8-GFP, to fluorescently label the plasma membrane of the cell body and neurite processes (TH::htau WT, mCD8-GFP). We then tested whether htau WT expression resulted in degeneration of these DA neurons. In young adults (1-week-old), the number of GFP-marked DA neurons in htau WT transgenic brains was comparable to control brains (TH::mCD8-GFP). At 2 weeks after eclosion, limited degeneration was observed in a small subset of PPL1 neurons expressing htau WT compared to age-matched controls. Remarkably, at 4 weeks after eclosion, we observed a significant loss of
DA neurons in transgenic flies relative to controls (Fig. 1). This loss occurred in two clusters of DA neurons: PPL1 and PPM3 (Fig. 1). Other FTDP-17 associated two tau variants of G272V and R406W, also showed similar effects (Fig. S1). To validate these htau WT-expressing cells may have undergone progressive degeneration, we characterized two components of the cell death signaling: cytochrome c and activated caspase 3-like caspase [53] for these htau WT-expressing cells and their GFP expressing controls in Drosophila. As expected, the expression of htau WT produced an abnormal increase in the expression of cytochrome c, before a surge of caspase 3-like caspase activation in 3-week-old flies expressing htau WT, relative to controls, suggesting the activation of cell death signaling in htau WT-expressing brains in Drosophila (Fig. S2). These results indicate a progressive degeneration of DA neurons in the brains of Drosophila expressing htau WT. To further confirm the effect of htau WT, we employed a second GAL4 driver, DDC-GAL4, which targets htau WT in both DA and serotonergic neurons. We confirmed that htau WT does induce the age-dependent DA neuron degeneration (Fig. S3). Together, these results show that expression of htau WT can induce progressive loss of DA neurons, manifesting the pathological DA degeneration in PD.

MAPT overexpression produces age-dependent motor and learning deficits

Similar to its role in mammals, the Drosophila nervous system utilizes many neurotransmitters to operate motor and cognitive behaviors. In the dopaminergic system, fruit fly use the same neurotransmitter as mammals to modulate a number of intricate neuronal circuits, ranging from those that control voluntary movement, mating, rewards, learning, and memory [41]. We tested whether expression of htau WT would alter motor behaviors. Using a negative geotaxis assay, we observed that TH::htau WT flies have a dramatically age-dependent climbing deficit; they showed significant loss of climbing ability compared to control flies at 4–6 weeks post-eclosion (Fig. 2a). In addition, we observed that flies expressing htau WT showed reduced spontaneous locomotion; they appeared “sluggish” and exhibited an increase in the number of “pauses” between bouts of spontaneous locomotion and travelled shorter distances during each bout (Fig. 2b).

Next, we performed short-term olfactory association assays to test whether expression of htau in DA neurons affects learning. To avoid the potential confound caused by motor deficits, we tested 3-week-old cohorts, an age at which the motor behavior of htau WT-expressing flies is comparable to that of controls. As expected, we observed modest but significant learning deficit in htau WT-expressing flies, which scored 10 % lower than the age-matched control groups (Fig. 2c). This result is consistent with recent empirical findings indicating that dopaminergic neurons projecting to the mushroom body are essential mediators of olfactory associative learning and memory [1, 4, 7, 39, 42]. Together, these results show that flies expressing htau WT in DA neurons manifest deficits in both motor and learning behaviors, which corroborate the observed age-dependent loss of DA neurons.

Aminergic and NPF neurons are relatively more vulnerable to MAPT expression

To determine how expression of htau WT would affect neurons using other types of neurotransmitters, we used additional GAL4 drivers including DVGLUT-GAL4 for glutamatergic neurons, GAD-GAL4 for GABAergic neurons, TPH-GAL4 for a subset of serotonergic neurons and NPFF-GAL4 for a subset of peptidergic F neurons. We did not observe loss of either GFP-marked glutamatergic or GABAergic cells (Fig. 3a–d, i); however, we observed that a subset of putative serotonergic neurons that project to the central complex and a subset of putative NPFF neurons were lost (Fig. 3e–i). These results are consistent with previous studies that have shown human tau expression can cause degeneration of several neuronal populations in Drosophila [23, 33, 56]. Together, these results demonstrate that htau WT can induce degeneration of DA neurons, serotonergic neurons, and NPFF neurons, whereas most glutamatergic and GABAergic neurons are unaffected by htau WT expression based on the fluorescent optical observation.

Formation of abnormal oligomeric tau and tangle-like pathology in DA neurons

Hyperphosphorylated tau has been suggested to accumulate as homogeneous or heterogeneous oligomers and subsequently form NFT [5]. To determine whether similar pathogenesis occurs in DA neurons that express htau WT, we used three common phosphoepitope antibodies (AT8, AT100, and AT180) and a polyclonal anti-tau antibody that have been widely utilized to characterize AD-like abnormal phosphorylation of tau in the postmortem brains of AD patients and animal models of tauopathies. Immunohistochemical analysis of TH::htau WT brains at different ages revealed that the morphology of DA neurons appeared normal in the first week, with no detectable morphological changes in the soma and neurites, suggesting that the neuronal architecture was normal in young adults (Fig. S4). At approximately 2 weeks post-eclosion, the staining pattern of the soma in some DA neurons has changed relative to the wild-type morphology, indicating that the cytoskeletal networks had been perturbed or disintegrated by this time (Fig. S4). Strikingly, after 3 weeks, the
phosphoepitope antibodies and a polyclonal anti-tau antibody began to reveal abnormal tangle-like morphology, resembling NFTs at the microscopic level in most DA neurons including those in PPL1 and PPM3. This result suggests that the appearance of abnormal NFTs in DA neurons is an age-dependent process (Fig. S4). To explore whether htau expression might also induce tangle pathology in general, we investigated other types of neurons expressing htauWT. Similar morphological change was also detected in a small subset of 5HT neurons, but no obvious alteration was detected in glutamatergic, GABAergic and NPF neurons in 6-week-old flies (Fig. S4). DA neurons that express htauWT exhibited largely pruned neurite branches at the distal end in 4-week-old individuals (Fig. S4). The few cells that survived until 6 weeks experienced soma shrinkage, which was dramatically different from age-matched, GFP-labeled DA neurons from control brains (Fig. 4a, S4). Moreover, we confirmed that at 6 weeks, these abnormal DA neurons expressing htauWT were stained by Congo red, a synthetic dye which recognized the

**Fig. 1** Expression of htauWT induces age-dependent DA neuron demise. Representative confocal images show mCD8-GFP-marked DA neurons in age-matched control fly brains (a–c TH::mCD8-GFP) and htauWT-expressing brains (d–f TH::htauWT, mCD8-GFP) of one- (a, d), two- (b, e), and four- (c, f) week-old individuals. Two clusters of DA neurons, PPL1 (protocerebral posterior lateral 1, circles) and PPM3 (protocerebral posterior medial 3, squares), are indicated. Scale bar 100 µm. Cell counts of PPL1 (g) and PPM3 (h) DA neurons from age-matched control and htauWT brains. Values shown represent Mean ± SEM (unpaired t test, **P < 0.001 at week 2 for g; *** P < 0.0001 at week 4 for g and h; n = 12)
abnormal β-sheet conformation of htau aggregations (Fig. 4b).

To determine whether these morphological changes were associated with structural changes in htau WT, we performed additional biochemical analyses on whole brain extracts from aged flies expressing TH::htau WT. We observed a gradual reduction of monomeric tau, and an increase in high-molecular-weight species, of human tau protein with increasing age (Fig. 4c). The appearance of the putative tau oligomers (>400 kDa) seemed to coincide with the onset of morphological change in DA neurons, which is in agreement with the hypothesis that tau oligomers may be toxic.

In order to more rigorously evaluate htau aggregates in DA neurons, we performed ultrastructure examination on sarkosyl-insoluble fraction extracted from htau transgenic brains. TEM revealed abundant filamentous aggregates formed in the extracts from fly brains of 4-week-old Drosophila expressing htau WT (Fig. 4d), but not in identically prepared sarkosyl-insoluble fraction from age-matched nontransgenic control brains. These negatively stained filaments were either helical (paired helical filaments, PHF) or straight (paired straight filaments, SF), with diameters of approximately 15–40 nm and the axial distance between consecutive wider portions of approximately 80–100 nm (Fig. 4d), resembling those PHFs found in AD [12]. Therefore, we suggest that the observed htau aggregates with an NFT-like pathology may be composed by PHF or SF.

To determine whether htau WT insolubility coincided with the appearance of the tangle-like morphology in DA neurons, we performed sarkosyl insolubility assays from brains at different ages. Western blotting of anti-htau revealed a modest reduction of insoluble tau monomer, and an increase with age, of several insoluble high-molecular-weight species between 75 and 400 kDa, including ~90, ~160, and ~240 kDa tau-positive bands (Fig. 4e). The formation of these insoluble high-molecular-weight aggregations apparently preceded the formation of tangles, which is consistent with the hypothesis that insoluble tau-containing aggregations may be responsible for the NFT-like pathology.

Effects of tau phosphorylation on neuron degeneration

Previous studies have suggested that tau phosphorylation is associated with AD and other tauopathies, although the role of phosphorylated state in disease pathogenesis remains controversial. To test whether the htau WT-induced DA neuron degeneration in Drosophila is related to its phosphorylation state, we expressed htau WT and phosphorylation site variants in DA neurons and compared their potential toxicity in aged fly brains. We focused on SP/TP sites, for which several proline-directed kinases such as glycogen synthase kinase 3 beta (GSK-3β) have been shown to modulate tau-mediated toxicity [23], and compared the effects of htau WT, htau AP, and htau E14. The AP mutation blocked proline-directed tau phosphorylation and the E14 mutation mimics phosphorylation of the endogenous 14 serine/threonine amino acids in htau. To confirm that htau WT can undergo phosphorylation in Drosophila DA cells, we performed western blots and observed a shift in the molecular weight of htau WT, from 75 to 60 kDa, in response to treatment with alkaline phosphatase (Fig. S5).
An earlier study showed that the htauAP mutation is less toxic than htauWT when expressed in Drosophila photoreceptors, but that the htauE14 mutation enhances neurotoxicity in the retina [49, 50]. Our results, using GMR-GAL4 driver to express these htau constructs in the retina, confirmed these observations (Fig. 5a, b). Surprisingly, the htau constructs appeared to have inverse effects when expressed in DA cells using TH-GAL4. TH::htauAP brains showed an increase in DA cell death, compared to flies expressing htauWT, and htauE14 resulted in less neurodegeneration than tauWT (Fig. 5c, d). Western blots validated that htauWT, htauAP, and htauE14 were expressed at similar levels, indicating that the phenotype is specific for the mutation in tau rather than expression of the transgenes (Fig. S5).

Fig. 3 Expression of htauWT fails to manifest neuronal loss in most glutamatergic and GABAergic neurons. a, b Representative confocal images show glutamatergic neurons of 4-week-old fly brains marked with mCD8-GFP. Several thousands of glutamatergic neurons with comparable GFP signals in both control (a, DVGLUT::mCD8-GFP) and htauWT brains (b, DVGLUT::htauWT, mCD8-GFP). c, d Representative confocal images show mCD8-GFP-marked GABAergic neurons in 6-week-old fly brain. Comparable GFP signals can be detected in both control (c GAD::mCD8-GFP) and htauWT brains (d GAD::htauWT, mCD8-GFP). e Representative confocal image shows a group of putative serotonergic neurons (TPH996::mCD8-GFP) projecting to central complex (arrows) at 4 weeks of age. f Representative confocal image shows the absence of GFP signals in neurons projecting to central complex in age-matched brain expressing htauWT (TPH996::htauWT, mCD8-GFP). g Representative confocal image shows two pairs of putative NPF neurons (NPF::mCD8-GFP) projecting to parietal central brains in control (f). In contrast, the GFP signals in a pair of NPF neurons that are located in the anterior region are absent in htauWT-expressing brains (NPF::htauWT, mCD8-GFP) at 4 weeks of age. Scale bar 100 μm. i Quantitative analyses show no significant differences between control (black bars) and htauWT (white bars) brains in DVGLUT, and GAD groups (unpaired t test, P = 0.54 for a and b; P = 0.60 for c and d, n = 4). In TPH and NPF groups, both the cell measurements (circles) between controls and htauWT are different (unpaired t test, ***P < 0.0001 for both e and f, and for g and h, n = 4).
It is possible that the severe neuronal phenotype induced by htau\(^{AP}\) is a developmental, but not a degenerative event. To circumvent potential developmental effects of htau\(^{AP}\) on DA neurons, we used a conditional expression system by incorporating temperature-sensitive GAL80\(^{ts}\) [27] in our model to predominantly, if not exclusively, expressing...
htau\textsuperscript{AP} in adult brains. By shifting temperature from 25 to 29 °C for newly enclosed adult flies, we induced transgene expressing, and observed that adult onset of htau\textsuperscript{AP} expression (GAL80\textsuperscript{ts}/UAS-htau\textsuperscript{AP}; TH-GAL4, UAS-CD8GFP/) induced severe neurodegeneration, similar to that of the continuously expression of htau\textsuperscript{AP} (TH::htau\textsuperscript{AP},

Fig. 5 Different phosphorylation site mutations of tau exert contrary effects on DA and histaminergic neurons. Representative SEM (a) and confocal (b) images of fly compound eyes. Control (GMR-GAL4) fly eyes show crystalline array of ~800 hexagonal-shaped ommatidia form the smooth external surface. Phalloidin staining reveals the underlying organization of each ommatidium with actin-rich rhabdomeres from seven photoreceptors being arranged in a trapezoidal format. Expression of three human tau transgenic alleles, htau\textsuperscript{AP14} (GMR::htau-AP), htau\textsuperscript{WT} (GMR::htau-WT), and htau\textsuperscript{E14} (GMR::htau-E14), produce different degrees of eye phenotypes and the severity ranking of eye defect is htau\textsuperscript{E14} > htau\textsuperscript{WT} > htau\textsuperscript{AP14} that is based on external eye size and roughness and the internal organization of photoreceptor cells (a, b). Scale bars 10 μm.

(c) Representative confocal images of control DA neurons marked with mCD8-GFP (TH::GFP), or co-expressing with either of the three human tau alleles (htau\textsuperscript{AP14}, TH::htau-AP; htau\textsuperscript{WT}, TH::htau-WT; and htau\textsuperscript{E14}, TH::htau-E14) from 1-, 2-, and 4-week-old brains. Circles indicate the PPL1 cluster. (d) Quantitative analysis presents DA neuron numbers in PPL1 cluster at different ages from control and three tau alleles. TH::GFP (purple), TH::htau-AP (green), TH::htau-WT (yellow) and TH::htau-E14 (red). Values shown represent mean ± SEM (unpaired t test compares individual tau allele to control in the age-indicated groups; **P < 0.001; ***P < 0.0001, n = 12)
GFP), while the control flies (TH::GFP) exhibited normal DA neurons (Fig. S6). Therefore, these data suggest the effect of htauAP on DA neuron was an age-dependent degeneration, but not a developmental defect.

Loss of vesicular dopamine release preceded tauopathy and neurodegeneration

Previously, we have shown that vesicular monoamine transporter (VMAT) reduced environmental toxins and mutant human parkin-induced toxicity [26, 44]. We reasoned that the loss of DA neurons resulting from the expression of human tau may be associated with a change in the DA storage and release machinery. To investigate this, we used the elliptical VMAT-pHluorin, with a pH-sensitive GFP conjugated in the first luminal loop of the 12 trans-membrane domains of VMAT to visualize the release of VMAT-pHluorin containing synaptic vesicle released to nerve terminals [34].

In wild-type fly brain, VMAT-pHluorin visualizes the synaptic vesicle-releasing regions of DA neurons in the fly brain. At one day after eclosion, VMAT was observed in many brain regions, including mushroom bodies, the fan-shaped body, and the protocerebral bridge, in wild-type flies (Fig. 6a) [31]. The single neuron of PPL1 and PPM3 data has been deposited in the database of Drosophila (http://www.flycircuit.tw). In contrast, the localization of VMAT to the mushroom body and protocerebral bridge was reduced in age-matched flies expressing htauWT (Fig. 6b). This decrease was most pronounced in 3-week-old fly brains compared to the wild-type fly brain (Fig. 6e, f). Remarkably, the VMAT-pHluorin signals in the mushroom body and protocerebral bridge were selectively absent from the htauAP brains at one-day post-eclosion, but remained prominent in controls (Fig. 6a, c). Interestingly, some neurons that project to the fan-shaped body appeared to be unaffected, as the VMAT-pHluorin signal appeared normal in both control and three htau (htauWT, htauAP and htauE14) expressing brains. Given that some TH-GAL4-marked neurons are not dopaminergic, we suspect that the unaffected VMAT-pHluorin labeling of the fan-shaped body might be a result of expression in those cells. To further investigate whether declines in VMAT-pHluorin localization to nerve terminals were indeed related to human tau-induced toxicity, DA neurons expressing of htauWT, htauAP, or htauE14, were compared in different ages (Fig. 6a–h). Surprisingly, the age-matched flies expressing htauAP had earlier and more profound loss of VMAT-pHluorin signals (Fig. 6c) than flies expressing htauWT or htauE14 (Fig. 6b, d). Variation in the GFP signals in brains co-expressing VMAT-pHluorin and htauWT or htauAP were not a result of variation in levels of VMAT-pHluorin expression, since levels of VMAT-pHluorin were similar in both experimental and control groups (Fig. 6i).

It is possible that htau could cause a general dysfunction of DA neurons resulting in multiple deficits in the DA release machinery. To determine whether expression of htauWT also disrupts calcium influx, we used a calcium-sensitive fluorescent protein, G-CaMP, to monitor changes in calcium. By visualizing 1-week-old live brains, we found that expression of htauWT did not alter the G-CaMP activity, compared to controls (Fig. 7a, b, e), suggesting that htauWT expression did not disrupt the general function of DA neurons during neuronal activation. However, at 3 weeks, we found that DA neurons expressing htauWT showed a minor but significant reduction of the G-CaMP signal compared to controls (Fig. 7c–e), consistent with overt DA neuronal degeneration around this age (Fig. 7c–e). In conclusion, these results suggest htauWT inhibits the VMAT-containing synaptic vesicle release to neuronal processes, before overt neuronal degeneration.

Discussion

In the present study, we used Drosophila DA neurons as a model to examine the pathogenic mechanism of PD-linked tauopathies. Expression of htauWT in these neurons resulted in age-dependent, progressive neurodegeneration and the deposition of abnormal polymeric tau protein aggregates. Systematic characterizations of functional, pathological, and behavioral readouts from these htauWT flies at different ages demonstrate a plausible pathogenic link between tau and vesicular DA release, as demonstrated by a fluorescent VMAT-pHluorin marker in the synaptic vesicle-releasing sites of DA neurons. This defect represents the earliest pathological manifestation that precedes the robust pathophysiological phenotypes and suggests that a functional inhibition of DA neurotransmission is a prelude of the hallmark lesions in our PD model.

The molecular components of DA signaling and homeostasis in Drosophila are similar to those in humans; both human and fly DA neurons express two types of transporters: (1) a vesicular monoamine transporter for transport of DA from the cytosol to the lumen of secretory vesicles [29]; (2) a plasma membrane DA transporter (DAT) for reuptake of exocytosed DA [18]. Therefore, despite the anatomical differences, Drosophila models of PD, as well as other human neurological disorders, can help contribute to our understanding of the pathogenic mechanism underlying these diseases [6]. This tau-PD Drosophila model is the first animal model to demonstrate that tau expression can cause degeneration of DA neurons, a hallmark of Parkinson’s disease.
Most motor symptoms and mild cognitive impairment of PD result primarily from progressive degeneration of DA neurons in the substantia nigra, but the mechanism through which pathogenic factors target DA neurons is not completely understood. While several toxic compounds are known to produce PD symptoms in animal models, only MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) has been firmly established as a cause of selective DA neuron toxicity. The issue of neuronal vulnerability, in terms of transporter or transmission mechanisms among individuals with monogenic PD risk factors, has rarely been addressed directly. One exception is a study that showed the expression of human α-synuclein in mice inhibited DA transmission by reducing the recycling of synaptic vesicles [37]. In addition, an association between DA metabolism and the death of DA neurons in PD has been postulated, and this association has been demonstrated in a α-synuclein PD model. Oxidative metabolites of DA may conjugate with α-synuclein to form an adduct of DA–α-synuclein, which may stabilize the toxic form of α-synuclein through covalent bound to DA quinone [11], while also promoting selective neurotoxicity [58]. Tau protein is ubiquitous in the brain, and has been shown to affect different types of neurons in various cell and animal models. A previous study showed that DA quinones, toxic metabolites that lead to PD, could promote the assembly of tau into fibrillar polymeric tau in vitro [15] which suggests a potential interplay between DA and tau in vivo and may provide a basis for the vulnerability of DA neurons.

One of the common themes of tau pathology is abnormal hyperphosphorylation of tau, originally identified in AD patients. However, the role of tau hyperphosphorylation in the pathophysiology of disease remains debated. In Drosophila photoreceptors, tau hyperphosphorylation is

![Image](image-url)
correlated with phenotypic severity [49], similar to the results observed in this study. However, we also determined that in DA neurons, the hypophosphorylated AP mutation increases toxicity while the hyperphosphorylated E14 mutation reduces toxicity. These data indicate that tau pathogenesis is likely influenced by multiple pathological mechanisms, because its phosphorylation mutations in DA and histaminergic neurons produce contrasting results. The hyperphosphorylation E14 mutation has a reduced binding affinity for microtubules, whereas the hypophosphorylation AP mutation has an increased affinity for microtubules. Thus, we suspect that hypophosphorylation AP tau mutation may profoundly block axonal transport and consequently inhibit synaptic vesicle transport. These notions raise the possibility that microtubule bound tau may partially contribute to tau pathogenesis in DA neurons due to its association with severity of phenotype in DA neurons; they are consistent with the concept that tau can compete with microtubule motor proteins and lead to abnormal axonal trafficking [51]. Interestingly, when tau was overexpressed in photoreceptors at late pupal stage, we observed that transport of rhodopsin to the photosensitive membrane, rhabdomere, was inhibited (Fig. S7). We postulate that decreased localization of VMAT to the nerve terminal caused by tau could contribute to the pathogenesis of PD.

We show that the expression of human tau evokes aberrant polymeric tau formation, during which PHF-like aggregates accumulate and NFT-like tangles develop in DA neurons; this occurs in an age-dependent manner. This is the first longitudinal study to directly examine tau tangle formation and other pathogenesis in DA neurons. In contrast to previous studies which show that tauopathy can evoke neuronal degeneration but cannot form neurofibrillary tangles in other types of neurons in Drosophila and Caenorhabditis [24, 56]; our results suggest that human tau can produce tangle pathology in DA neurons, similar to the tau neurofibrillary tangles seen in PD patients. We suspect that the difference of tau manifestations is likely due to dopamine modifications and perhaps different amount of tau proteins in each neuron and believe that our tau-PD Drosophila model offers a robust animal model that can facilitate to investigate modification of tau pathogenesis.

Fig. 7 Expression of htauWT causes age-dependent loss of G-CaMP activities. G-CaMP signal reveals Ca2+ activity in control DA neurons (TH::G-CaMP) from 1-week-old (a) and 3-week-old (c) flies. Expression of htauWT shows comparable G-CaMP signals compared to control group at 1 week (b), but the signals are reduced 10 % at 3 weeks (d). The G-CaMP activities are represented by thermal color from the higher (red) to lower intensity (blue). Scale bar 100 μm. e Quantitative analysis shows G-CaMP activities in control brains (TH::G-CaMP, black bars) and in htauWT brains (TH::G-CaMP, htauWT, red bars) at indicated ages. Values shown represent Mean ± SEM (unpaired t test; **P < 0.001).
Our neuropathological observations reveal at least two distinct molecular mechanisms of tau pathogenesis in DA neurons for PD. We show that failure of VMAT-containing synaptic vesicle release to nerve terminals is an early pathogenic manifestation, and the formation of neurofibrillary tangle-like pathology in the soma of DA neurons is a late-stage of tauopathy, providing pathological evidence for why MAPT may be a strong risk factor for idiopathic PD. The correction or prevention of the deficit in vesicular DA storage may be appropriate target for early therapeutic intervention.

Acknowledgments We thank J. Hirsh, R. Axel, M. Feany, J.-L. Juang, and Bloomington Drosophila Stock Center for fly strains. We are grateful to Tzu-Kang Sang and Don Ready for their critical comments and suggestions, and Hong-Dar Wang, Jui-Chou Hsu, Kathy Sang for their suggestions on this manuscript. We thank the support from Imaging Core of the Brain Research Center in National Tsing Hua University. This work is supported by National Science Council Grant 98-2311-B-007-014-MY3 and National Tsing Hua University Grant N2612E1 (H.-Y. C).

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Aso Y, Herb A, Ogueta M, Siwanowicz I, Templier T, Friedrich AB, Ito K, Scholz H, Tanimoto H (2012) Three dopamine pathways induce aversive odor memories with different stability. PLoS Genet 8:e1002768
2. Benzer S (1967) Behavioral mutants of Drosophila isolated by countercurrent distribution. Proc Nat Acad Sci USA 58:1112–1119
3. Berg I, Nilsson KP, Thor S, Hammarstrom P (2010) Efficient imaging of amyloid deposits in Drosophila models of human amyloidoses. Nat Protoc 5:935–944
4. Berry JA, Cervantes-Sandoval I, Nicholas EP, Davis RL (2012) Vesicular monoamine transporter increases motor activity for why DA storage may be appropriate target for early therapeutic intervention.

11. Conway KA, Rocjet JC, Bieganski RM, Lansbury PT Jr (2001) Genetic animal models of Parkinson’s disease. Neuron 66:646–661
12. Crowther RA (1991) Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc Nat Acad Sci USA 88:2288–2292
13. Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson’s disease. Neuron 73:685–697
14. de Callignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Saha RA, Ashe K, Carlson GA, Spires-Jones TL, Hymn BT (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 73:685–697
15. Dixit R, Ross JL, Goldman YE, Holzbaur EL (2008) Differential regulation of dynin and kinesin motor proteins by tau. Science 319:1086–1089
16. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, Wang L, Zuchner S, Konidari I, Wang G, Singer C, Nahab F, Scott B, Stajich JM, Perciak-Vance M, Haines J, Vance JM, Martin E (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74:97–109
17. Farrer M, Skipper L, Berg M, Bisciglio G, Hansen M, Hardy J, Adam A, Gwinn-Hardy K, Aslly J (2002) The tau H1 haplotype is associated with Parkinson’s disease in the Norwegian population. Neurosci Lett 322:83–86
18. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606–612
19. Guillot TS, Miller GW (2009) Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol 39:149–170
20. Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldswurm S, Tolosa E, Borroni B, Pastor P, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Muller U, Schellenberg GD (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43:699–705
21. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiat 55:181–184
22. Hutton M, Lendon CL, Rizzu P, Baker M, Froehlich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Peter K, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, J, Adam A, Gwinn-Hardy K, Aslly J (2002) The tau H1 haplotype is associated with Parkinson’s disease in the Norwegian population. Neurosci Lett 322:83–86
23. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Swieten JC, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldswurm S, Tolosa E, Borroni B, Pastor P, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Muller U, Schellenberg GD (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43:699–705
24. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiat 55:181–184
25. Hutton M, Lendon CL, Rizzu P, Baker M, Froehlich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Peter K, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, J, Adam A, Gwinn-Hardy K, Aslly J (2002) The tau H1 haplotype is associated with Parkinson’s disease in the Norwegian population. Neurosci Lett 322:83–86
27. Lee T, Luo L (2001) Mosaic analysis with a repressible cell marker (MARC M) for Drosophila neural development. Trends Neurosci 24:251–254

28. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121–1159

29. Liu Y, Edwards RH (1997) The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 20:125–156

30. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E (2003) Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 24:1079–1085

31. Mao Z, Davis RL (2009) Eight different types of dopaminergic neurons innervate the Drosophila mushroom body neuropil: anatomical and physiological heterogeneity. Front Neural Circ 3:5

32. Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, Pan Y, Zeger SL, Manolio TA, Lecourtois M, Parmentier ML (2011) Important neuronal anatomical and physiological heterogeneity: genetics and pathogenesis. Annu Rev Pathol 6:193–222

33. Mershin A, Pavlopoulos E, Fitch O, Braden BC, Nanopoulos DV, Skoulakis EM (2004) Learning and memory deficits upon TAU accumulation in Drosophila mushroom body neurons. Learn Mem 11:277–287

34. Miesenbock G, De Angeli DA, Rothman JE (1998) Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. Nature 394:192–195

35. Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62:218–229

36. Myers AJ, Pittman AM, Zhao AS, Rohrer K, Kaleem M, Marlowe L, Lees A, Leung D, McKeith IG, Perry RH, Morris CM, Trojanowski JQ, Clarke C, Karlawish J, Arnold S, Forman MS, Van Deerlin V, de Silva R, Hardy J (2007) The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis 25:561–570

37. Nemani VM, Lu W, Berve G, Nakamura K, Ono B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RD (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65:66–79

38. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Dohmen HF, Guseila JF, Nichols WC, Foroud T, Myers RH (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124:593–605

39. Qiu H, Cressy M, Li W, Corvus Corax, Izzi SA, Dubnau J (2012) Gamma neurons mediate dopaminergic input during aversive olfactory memory formation in Drosophila. Curr Biol 22:608–614

40. Reiff DF, Ihrig A, Guerrero G, Isacoff EY, Joesch M, Nakaj J, Borst A (2005) In vivo performance of genetically encoded indicators of neural activity in flies. J Neurosci 25:4766–4778

41. Riemsperger T, Israel G, Coulom H, Neuser K, Seugnet L, Kume K, Iche-Torres M, Cassar M, Strauss R, Preat T, Hirsh J, Birman S (2011) Behavioral consequences of dopamine deficiency in the Drosophila central nervous system. Proc Nat Acad Sci USA 108:834–839

42. Riemsperger T, Voller T, Stock P, Buchner E, Fiala A (2005) Punishment prediction by dopaminergic neurons in Drosophila. Curr Biol 15:1953–1960

43. Rovelet-Lecruix A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchik C, Feuillite S, Bric A, Vercelletto M, Dubas F, Frebourg T, Campion D (2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38:24–26

44. Sang TK, Chang HY, Lawless GM, Ratnaparkhi A, Mee L, Ackerson LC, Maidment NT, Krantz DE, Jackson GR (2007) A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. J Neurosci 27:981–992

45. Shulman JM, De Jager PL, Feany MB (2011) Parkinson’s disease: genetics and pathogenesis. Annu Rev Pathol 6:193–222

46. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg PA, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kruger R, Federoff M, Klein C, Goate A, Lulme J, Monin B, Nallais MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Poote KD, Fernandez HH, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deutsch G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T (2009) Genome-wide association study reveals genetic risk underlining Parkinson’s disease. Nat Genet 41:1308–1312

47. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Dutra A, Nussbaum R, Lincoln S, Crawford A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptist M, Miller D, Blacanto V, Hardy J, Gwinn-Hardy K (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302:840–841

48. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakos R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840

49. Steinihilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB (2007) Tau phosphorylation sites work in concert to promote neurototoxicity in vivo. Mol Biol Cell 18:5060–5068

50. Steinihilb ML, Dias-Santagata D, Mulkerns EE, Shulman JM, Biernat J, Mandelkow EM, Feany MB (2007) S/P and T/P tau phosphorylation is critical for tau neurotoxicity in vivo. Mol Biol Cell 18:5060–5068

51. Talmat-Amar Y, Arribat Y, Redt-Clouet C, Feuillette S, Bouge RA (2005) In vivo performance of genetically encoded calcium indicator in Drosophila mushroom body neurons. Curr Biol 22:608–614

52. Tully T, Quina W (1985) Classical conditioning and retention in normal and mutant Drosophila melanogaster. J Comp Physiol A Sens Neural Behav Physiol 157:263–277

53. Varkey J, Chen P, Jemmerson R, Abrams JM (1999) Altered activity in the fly brain. Cell 112:271–282

54. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Gentile C, Kume K, Iche-Torres M, Cassar M, Strauss R, Brayer C, Kolachana BS, Weinberger DR, Sawcer SJ, Robins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009) The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the Campaign cohort. Brain 132:2958–2969

55. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB (2001) Tauopathy in Drosophila:
neurodegeneration without neurofibrillary tangles. Science 293:711–714
57. Wray S, Lewis PA (2010) A tangled web—tau and sporadic Parkinson’s disease. Front Psychiat 1:150
58. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600–606
59. Zabetian CP, Hutter CM, Factor SA, Nutt JG, Higgins DS, Griffith A, Roberts JW, Leis BC, Kay DM, Yearout D, Montimurro JS, Edwards KL, Samii A, Payami H (2007) Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson’s disease. Ann Neurol 62:137–144
60. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Mohr B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607